Alpha Tau to Participate in September Investor Conferences
JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd.
DRTS - Alpha Tau Medical Ltd
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$18.00
DETAILS
HIGH:
$30.00
LOW:
$8.00
MEDIAN:
$16.00
CONSENSUS:
$18.00
UPSIDE:
19.76%
Stock News
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
- IMPACT, a multicenter pilot study of Alpha DaRT ® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total of 48 treated patients, driven by overwhelming demand from patients and clinicians - - Alpha DaRT is delivered as a one-time add-on alongside standard first-line chemotherapy, an approach supported by the favorable safety profile observed in the earlier Israeli and Canadian studies - - With data release targeted for early 2027, IMPACT is intended to inform the design of a planned pivotal study, and anchors a global pancreatic cancer program that also includes the ACAPELLA trial in France and a study at the University of Verona - JERUSALEM, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the completion of patient enrollment in its IMPACT study (Intratumoral Pancreatic Alpha Combination Trial) - a multicenter pilot study evaluating intratumoral Alpha DaRT in combination with first-line chemotherapy for patients with newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma.
PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrast
PAVmed (NASDAQ: PAVM - Get Free Report) and Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability. Profitability This table compares PAVmed and Alpha
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) - - Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting - - Median overall survival of 18.2 months and median progression-free survival of 5.4 months compare favorably with historical benchmarks for pembrolizumab monotherapy in this setting of 12.3 months and 3.2 months, respectively - - No Alpha DaRT-associated serious adverse events were observed; the only two Alpha DaRT-associated adverse events were Grade 1 (mild) - - Results build on foundation of Alpha DaRT monotherapy data in head and neck cancer, and lend support to Alpha Tau's ongoing clinical strategy exploring the combination approach, which the Company continues to discuss with the U.S. FDA - - Trial recruitment is now complete, having met the pre-specified success criterion of its Simon two-stage adaptive design: more than six patients responding to the treatment - JERUSALEM, July 21, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau” or the “Company”) (Nasdaq: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced positive results from a clinical study evaluating Alpha DaRT in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma (HNSCC), in which the combination produced a 100% objective response rate and a median overall survival of 18.2 months among evaluable patients.
Alpha Tau Medical (NASDAQ:DRTS) Trading 7.1% Higher – Here’s Why
Alpha Tau Medical Ltd. (NASDAQ: DRTS - Get Free Report) shares rose 7.1% on Friday. The company traded as high as $12.53 and last traded at $12.7280. 196,591 shares were traded during trading, a decline of 67% from the average daily volume of 591,564 shares. The stock had previously closed at $11.88. Analysts Set New
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson
New Strong Sell Stocks for July 7th
AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.
New Strong Sell Stocks for July 2nd
DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah Medical Center in Israel
Alpha Tau Medical: A Lot Of Shots On Goal
Alpha Tau Medical (DRTS) is pioneering localized alpha particle radiation for solid tumors, with strong recent clinical and partnership momentum. DRTS's innovative and patented "Alpha DaRT" technology overcomes prior range limitations and shows high response rates in multiple indications. This month's recent Tolmar partnership brings $35M in upfront capital and potential milestones, supporting DRTS's cash runway through 2027 amid ongoing trials.
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
- Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolmar's commercial leadership to transform the U.S. uro-oncology landscape - Collaboration elevates prostate cancer as a core strategic focus, backed by Tolmar's initial $15M manufacturing investment, $20M equity infusion at $11.99 per share (25% premium to 30-day VWAP), and up to $161.5M in clinical, regulatory and commercial milestones for the first indication - Agreement grants Tolmar exclusive U.S. commercialization rights for prostate cancer, with an option to expand into bladder cancer subject to additional payments - Alpha Tau to manufacture Alpha DaRT for Tolmar's commercialization, to be sold to Tolmar at 60% of the onward net sales price, subject to certain adjustments JERUSALEM and DUBLIN, June 03, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW), developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, and Tolmar International Ltd.
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of three prospective Phase I/II studies in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates encouraging median overall survival (mOS) across chemotherapy-naive, second-line, and heavily pretreated patient populations - - Patients treated with Alpha DaRT after 1st line chemotherapy reached median overall survival (mOS) of 11.2 and 11.1 months in metastatic and locally advanced disease, respectively, from the date of trial enrollment, compared to ~4 - 6 months for metastatic patients and ~ 9 months for locally advanced patients with second-line chemotherapy, based on published historical data - - Favorable safety profile observed across the Alpha DaRT trials, with treatment-associated adverse events reported in 36% of subjects and Grade ≥3 events in 9%, with no treatment-related deaths and no chronic toxicity; all Grade ≥3 events resolved - - Following these strong survival data, Company next turns to anticipated completion of recruitment in the multicenter U.S. IMPACT pancreatic cancer trial, which is exploring the ability of Alpha DaRT, in combination with initiation of front-line chemotherapy, to deliver a potent and focused local dose without exacerbating the harsh systemic side effects of standard chemotherapy - JERUSALEM, June 01, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced positive overall survival and safety results from a pooled analysis of three prospective Phase I/II clinical studies evaluating endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
Alpha Tau Medical NASDAQ: DRTS outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company's most important trials are “coming to a head” over the coming months.
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company's first U.S. pivotal study - - Pooled data from two pancreatic cancer trials presented at Digestive Disease Week (DDW) 2026 demonstrated 100% local disease control and favorable safety, the first oral presentation of Alpha DaRT ® pancreatic data at a premier international gastroenterology conference - - Abstracts accepted for presentation at the 2026 ASCO Annual Meeting and at the AHNS 12th International Conference on Head and Neck Cancer, reflecting growing scientific recognition across multiple solid tumor indications - - FDA approval of an IDE supplement to expand the IMPACT pancreatic cancer trial to patients receiving gemcitabine with Abraxane ® (nab-paclitaxel) and recruit additional patients - - First patient successfully treated for pancreatic cancer in Europe at CHU Grenoble Alpes under the multicenter ACAPELLA trial in France, and first patient successfully treated in Italy at the University of Verona's Pancreas Institute - - Cash, cash equivalents, short-term deposits and restricted deposits balance of $80.2 million provides runway for continued clinical advancement and commercial preparation - JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported first quarter 2026 financial results and provided a corporate update.
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in May 2026.
Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally
Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) rose Monday after the company reported interim results from its U.S. trial of Alpha DaRT in patients with recurrent glioblastoma.
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
Alpha Tau Medical NASDAQ: DRTS presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical investigators describing initial tumor responses and safety observations from the pilot trial.
Price Targets
Alpha Tau price target raised to $30 from $17 at Barclays
$30.00
(was $14.33)
Alpha Tau to
·
Barclays
Alpha Tau price target raised to $16 from $15 at H.C. Wainwright
$16.00
(was $13.69)
H.C. Wainwright
Alpha Tau price target raised to $17 from $15 at Barclays
$17.00
(was $10.58)
Barclays
Barclays Starts Alpha Tau Medical Ltd. (DRTS) at Overweight
$15.00
(was $10.29)
Lukas Shumway
·
Barclays
Alpha Tau price target raised to $8 from $5 at Piper Sandler
$8.00
(was $10.03)
Piper Sandler
Alpha Tau price target raised to $15 from $12 at H.C. Wainwright
$15.00
(was $10.34)
H.C. Wainwright
Alpha Tau price target raised to $12 from $9 at H.C. Wainwright
$12.00
(was $7.50)
Yi Chen
·
H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
$9.00
(was $3.59)
Yi Chen
·
H.C. Wainwright
Piper Sandler Reiterates Overweight Rating on Alpha Tau Medical Ltd. (DRTS)
$7.00
(was $2.91)
Jason Bednar
·
Piper Sandler
Piper Sandler Maintains Overweight on Alpha Tau Medical, Lowers Price Target to $12
$12.00
(was $3.75)
Piper Sandler